JP2015510886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510886A5 JP2015510886A5 JP2014561101A JP2014561101A JP2015510886A5 JP 2015510886 A5 JP2015510886 A5 JP 2015510886A5 JP 2014561101 A JP2014561101 A JP 2014561101A JP 2014561101 A JP2014561101 A JP 2014561101A JP 2015510886 A5 JP2015510886 A5 JP 2015510886A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydroxy
- substituted
- compound according
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- -1 C 1 -C 5 alkyl Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 2
- GOVYBPLHWIEHEJ-UHFFFAOYSA-N tubastatin A Chemical group C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 GOVYBPLHWIEHEJ-UHFFFAOYSA-N 0.000 claims 2
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- BHUZLJOUHMBZQY-YXQOSMAKSA-N N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide Chemical compound C1=CC(CO)=CC=C1[C@H]1O[C@@H](C=2C=CC(NC(=O)CCCCCCC(=O)NO)=CC=2)O[C@@H](CSC=2OC(=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BHUZLJOUHMBZQY-YXQOSMAKSA-N 0.000 claims 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229940099039 velcade Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607803P | 2012-03-07 | 2012-03-07 | |
| US61/607,803 | 2012-03-07 | ||
| US201261618150P | 2012-03-30 | 2012-03-30 | |
| US61/618,150 | 2012-03-30 | ||
| US201261648946P | 2012-05-18 | 2012-05-18 | |
| US61/648,946 | 2012-05-18 | ||
| US201261651595P | 2012-05-25 | 2012-05-25 | |
| US201261651896P | 2012-05-25 | 2012-05-25 | |
| US61/651,595 | 2012-05-25 | ||
| US61/651,896 | 2012-05-25 | ||
| US201261674942P | 2012-07-24 | 2012-07-24 | |
| US61/674,942 | 2012-07-24 | ||
| US201261715379P | 2012-10-18 | 2012-10-18 | |
| US61/715,379 | 2012-10-18 | ||
| PCT/US2013/029521 WO2013134467A1 (en) | 2012-03-07 | 2013-03-07 | Selective histone deactylase 6 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510886A JP2015510886A (ja) | 2015-04-13 |
| JP2015510886A5 true JP2015510886A5 (enExample) | 2016-05-19 |
| JP6233812B2 JP6233812B2 (ja) | 2017-11-22 |
Family
ID=49117326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561101A Expired - Fee Related JP6233812B2 (ja) | 2012-03-07 | 2013-03-07 | 選択的ヒストンデアセチラーゼ6阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2822926A4 (enExample) |
| JP (1) | JP6233812B2 (enExample) |
| AU (1) | AU2013230881A1 (enExample) |
| CA (1) | CA2866707A1 (enExample) |
| WO (1) | WO2013134467A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10287255B2 (en) | 2014-03-12 | 2019-05-14 | Chong Kun Dang Pharmaceutical Corp. | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same |
| WO2015154065A1 (en) | 2014-04-05 | 2015-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination |
| WO2016010879A1 (en) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| LT3177612T (lt) | 2014-08-04 | 2022-06-10 | Nuevolution A/S | Pirimidino dariniai, pakeisti pasirinktinai kondensuotu heterociklilu, tinkami uždegiminių, metabolinių, onkologinių ir autoimuninių ligų gydymui |
| CN115920007A (zh) * | 2014-10-24 | 2023-04-07 | 阿斯利康(瑞典)有限公司 | 组合 |
| US9993459B2 (en) | 2015-01-08 | 2018-06-12 | Universiteit Gent | Selective HDAC6 inhibitors and uses thereof |
| TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
| ES2770123T3 (es) | 2015-02-02 | 2020-06-30 | Forma Therapeutics Inc | Acidos 3-alquil-4-amido-bicíclicos [4,5,0]hidroxámicos como inhibidores de HDAC |
| EP3330259B1 (en) | 2015-07-27 | 2020-06-10 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| CN107922362B (zh) | 2015-07-27 | 2021-06-15 | 株式会社钟根堂 | 作为组蛋白脱乙酰基酶6抑制剂的1,3,4-噁二唑磺酰胺衍生化合物及含有其的医药组合物 |
| EP3328844B1 (en) | 2015-07-27 | 2019-11-27 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same |
| PT3331864T (pt) | 2015-08-04 | 2022-01-18 | Chong Kun Dang Pharmaceutical Corp | Compostos derivados de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica compreendendo os mesmos |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| EP3615025A4 (en) * | 2017-04-26 | 2020-11-25 | The Board of Trustees of the University of Illionis | NRF AND HIF ACTIVATORS / HDAC INHIBITORS AND THERAPEUTIC METHODS USING THEM |
| WO2019054865A1 (en) * | 2017-09-14 | 2019-03-21 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T-cell based immunotherapy |
| NL2019548B1 (en) * | 2017-09-14 | 2019-03-27 | Academisch Ziekenhuis Leiden | T-cell based immunotherapy |
| CN108191748A (zh) * | 2018-01-24 | 2018-06-22 | 齐鲁师范学院 | 一种含芳杂环氨基肟类化合物、制备方法及其用途 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3976602A4 (en) | 2019-05-31 | 2023-05-31 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF |
| AU2020284167B2 (en) | 2019-05-31 | 2023-05-11 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| KR102331206B1 (ko) * | 2019-12-09 | 2021-11-25 | 계명대학교 산학협력단 | 히스톤 탈아세틸효소 억제 활성을 갖는 신규 화합물 및 이의 의학적 용도 |
| MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
| TWI872177B (zh) | 2019-12-20 | 2025-02-11 | 丹麥商紐韋盧森公司 | 對核受體具有活性之化合物 |
| KR102537616B1 (ko) | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102537615B1 (ko) | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| KR102576148B1 (ko) | 2020-04-13 | 2023-09-07 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| TWI864293B (zh) * | 2020-06-08 | 2024-12-01 | 安基生技新藥股份有限公司 | 選擇性hdac6抑制劑及其用途 |
| JP7691716B2 (ja) * | 2020-06-26 | 2025-06-12 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 選択的ヒストンデアセチラーゼ6阻害剤 |
| BR112023000560A2 (pt) | 2020-07-14 | 2023-01-31 | Chong Kun Dang Pharmaceutical Corp | Compostos inovadores como inibidor de histona desacetilase 6 e composição farmacêutica que compreende os mesmos |
| KR102685058B1 (ko) | 2020-09-02 | 2024-07-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102905373B1 (ko) | 2021-04-08 | 2025-12-29 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102904231B1 (ko) | 2022-04-07 | 2025-12-29 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| US20250214983A1 (en) | 2022-07-15 | 2025-07-03 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole triazole compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same |
| KR20240035172A (ko) | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| TW202426439A (zh) | 2022-10-14 | 2024-07-01 | 韓商鐘根堂股份有限公司 | 作為組蛋白去乙醯酶6抑制劑之磺醯亞胺化合物以及含彼之醫藥組合物 |
| CN120917017A (zh) | 2023-02-28 | 2025-11-07 | 株式会社 钟根堂 | 噁二唑衍生物化合物及包含其的药物组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU758903B2 (en) | 1998-11-26 | 2003-04-03 | Pentapharm Ag | Transport system conjugate |
| US20030070691A1 (en) * | 2000-08-03 | 2003-04-17 | Anthony Giletto | Biocide formation via ozonation |
| US7034109B2 (en) | 2000-10-13 | 2006-04-25 | Christophe Bonny | Intracellular delivery of biological effectors |
| US7033597B2 (en) | 2000-10-13 | 2006-04-25 | Université de Lausanne | Intracellular delivery of biological effectors |
| WO2003070691A1 (en) * | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | N-hydroxycarboxamide derivative |
| JP2007509930A (ja) * | 2003-10-27 | 2007-04-19 | エス*バイオ プライベート リミティッド | アシル尿素およびスルホニル尿素が結合したヒドロキサマート |
| WO2006017216A1 (en) * | 2004-07-12 | 2006-02-16 | Merck & Co., Inc. | Histone deacetylase inhibitors |
| US20080269282A1 (en) * | 2004-08-02 | 2008-10-30 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| US20070066646A1 (en) * | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| US20110212969A1 (en) * | 2010-02-26 | 2011-09-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US20150197497A1 (en) * | 2011-06-24 | 2015-07-16 | Dana-Farber Cancer Institute, Inc. | Selective inhibitors of histone deacetylase isoform 6 and methods thereof |
-
2013
- 2013-03-07 JP JP2014561101A patent/JP6233812B2/ja not_active Expired - Fee Related
- 2013-03-07 CA CA2866707A patent/CA2866707A1/en not_active Abandoned
- 2013-03-07 AU AU2013230881A patent/AU2013230881A1/en not_active Abandoned
- 2013-03-07 EP EP13758416.5A patent/EP2822926A4/en not_active Withdrawn
- 2013-03-07 WO PCT/US2013/029521 patent/WO2013134467A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015510886A5 (enExample) | ||
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| JP2017528524A5 (enExample) | ||
| JP2012523457A5 (enExample) | ||
| HRP20140975T1 (hr) | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze | |
| JP2013531029A5 (enExample) | ||
| RU2008112683A (ru) | Ингибиторы fap | |
| EA201591000A1 (ru) | Пирролобензодиазепины | |
| NZ717119A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
| JP2009536620A5 (enExample) | ||
| AR067886A1 (es) | Derivados de acido azabifenilaminobenzoico | |
| CO6321258A2 (es) | Benzofuropirimidinonas como inhibidores de proteina de quinasa | |
| JP2014508804A5 (enExample) | ||
| JP2015517574A5 (enExample) | ||
| ES2496592T3 (es) | Proceso para la preparación de Imatinib y compuestos intermedios del mismo | |
| EA201190119A1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| RU2007125726A (ru) | Новое производное антраниловой кислоты или его соль | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2009144538A (ru) | Новые циклические пептидные соединения | |
| JP2008513485A5 (enExample) | ||
| JP2006509842A5 (enExample) | ||
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| RU2013151867A (ru) | Ингибиторы гидролазы амидов жирных кислот для лечения боли | |
| PE20200960A1 (es) | Inhibidor de receptor del factor de crecimiento epidermico |